home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Possibility For Polycystic Kidney Disease Treatment

  March, 2 2004 10:16
your information resource in human molecular genetics
In the April issue of Nature Medicine, Vicente Torres and colleagues report a new treatment for polycystic kidney disease (PKD), the fourth leading cause of kidney failure in the US.

PKD is a genetic disorder in which kidneys become overgrown with fluid-filled cysts. The authors tested the drug OPC31260, which blocks an important receptor in kidney cells, in a mouse model of autosomal dominant PKD, the most common form of the disease. The drug blocked disease development in the mice, reducing the number of kidney cysts and preventing the kidneys from becoming enlarged.

The authors say OPC31260 and similar drugs should be safe in clinical studies because they specifically target the kidneys. Other drugs targeting the same receptor are currently in clinical trials for diseases such as congestive heart failure and cirrhosis.

Author contact:

Vicente E. Torres
Mayo Clinic
Rochester, MN
Tel: +1 507 284 2908
E-mail: torres.vicente@mayo.edu

Also available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.